Hyperandrogenism Medical Services in China

Hyperandrogenism is a clinical endocrine disorder characterized by excessive production or heightened peripheral activity of androgens—male sex hormones such as testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS)—in individuals assigned female at birth. It is not a disease in itself but rather a biochemical and phenotypic manifestation of underlying pathophysiology, most commonly associated with polycystic ovary syndrome (PCOS), which accounts for approximately 70–80% of cases. Other etiologies include non-classical congenital adrenal hyperplasia (NCAH), adrenal or ovarian tumors, Cushing’s syndrome, hyperprolactinemia, and insulin resistance–driven ovarian theca cell overstimulation. Pathogenesis involves dysregulation across the hypothalamic–pituitary–ovarian–adrenal axes, often amplified by genetic susceptibility, chronic low-grade inflammation, and adipose tissue dysfunction that enhances aromatase activity and androgen conversion. Epidemiologically, hyperandrogenism affects an estimated 5–10% of women of reproductive age globally, with prevalence rising to 12–20% in populations with high obesity rates or PCOS diagnosis. Risk factors include obesity (especially central adiposity), family history of PCOS or early-onset metabolic disease, insulin resistance, sedentary lifestyle, and exposure to endocrine-disrupting chemicals. Clinical manifestations span dermatologic (hirsutism, acne, androgenic alopecia), menstrual (oligo- or amenorrhea), metabolic (dyslipidemia, impaired glucose tolerance), and reproductive domains (anovulation, subfertility). Importantly, hyperandrogenism significantly impairs quality of life: patients report higher rates of anxiety, depression, body image distress, sexual dysfunction, and social withdrawal—often underrecognized in routine care. Untreated, it confers long-term risks including type 2 diabetes, cardiovascular disease, endometrial hyperplasia, and infertility. Early diagnosis requires integrated assessment: detailed history, physical exam (Ferriman-Gallwey score for hirsutism), serum androgen panel (total/free testosterone, DHEAS, androstenedione), AMH, pelvic ultrasound, and exclusion of malignancy or rare endocrinopathies. Management must be individualized—not solely hormone-suppressive—but centered on metabolic health, psychological support, and fertility preservation, especially within reproductive medicine departments where multidisciplinary coordination with endocrinology, dermatology, nutrition, and mental health specialists is essential.

Hyperandrogenism refers to excessive circulating levels of androgens—primarily testosterone, dihydrotestosterone (DHT), dehydroepiandrosterone sulfate (DHEA-S), and androstenedione—or their clinical manifestations, including hirsutism, acne, alopecia, oligo- or anovulation, and metabolic disturbances. It is a hallmark feature of polycystic ovary syndrome (PCOS), the most common endocrine disorder among women of reproductive age, affecting approximately 6–12% globally. PCOS accounts for up to 70–80% of cases of hyperandrogenism in reproductive-aged women and is characterized by ovarian theca cell hyperplasia, insulin resistance–driven ovarian and adrenal androgen excess, and dysregulation of gonadotropin-releasing hormone (GnRH) pulse frequency leading to elevated luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH). Other common endocrine causes include nonclassic congenital adrenal hyperplasia (NCAH), particularly due to 21-hydroxylase deficiency (CYP21A2 mutations), which presents with mild-to-moderate androgen excess, often unmasked by stress or glucocorticoid withdrawal. Adrenal tumors (e.g., androsteroma), ovarian stromal hyperthecosis, and virilizing ovarian or adrenal malignancies—though rare—must be excluded in cases of rapid-onset virilization, clitoromegaly, or markedly elevated DHEA-S (>700–800 µg/dL) or testosterone (>150 ng/dL). Functional hyperandrogenism may also arise from severe insulin resistance syndromes (e.g., type A insulin resistance, lipodystrophy, or Rabson–Mendenhall syndrome), where hyperinsulinemia directly stimulates ovarian theca cells and suppresses hepatic sex hormone–binding globulin (SHBG) synthesis, increasing free testosterone bioavailability. Triggers of clinical exacerbation include weight gain—particularly central adiposity—which amplifies adipose tissue aromatase activity, local cortisol regeneration via 11β-HSD1, and insulin resistance; peripartum hormonal shifts; initiation of progestin-only contraceptives with androgenic activity (e.g., levonorgestrel, norethindrone); and chronic psychological stress, which activates the hypothalamic–pituitary–adrenal (HPA) axis and may augment adrenal androgen output. Key risk factors encompass obesity (BMI ≥25 kg/m²), especially visceral adiposity, which independently correlates with SHBG suppression and amplified LH pulsatility; early menarche (<11 years) and premature pubarche, both associated with heightened lifetime androgen exposure and metabolic programming; and history of gestational diabetes or macrosomia, reflecting underlying insulin resistance susceptibility. Genetic factors are strongly implicated: genome-wide association studies (GWAS) have identified multiple susceptibility loci—including DENND1A, THADA, LHCGR, FSHR, and YAP1—involved in gonadotropin signaling, ovarian folliculogenesis, and insulin action. Familial clustering is evident, with first-degree relatives of women with PCOS exhibiting higher prevalence of hyperandrogenism, insulin resistance, and cardiovascular risk markers. Epigenetic modifications—such as DNA methylation changes in genes regulating steroidogenesis (e.g., CYP11A1, CYP17A1) and insulin signaling—may mediate transgenerational transmission, particularly following maternal hyperandrogenemia or gestational hyperglycemia. Environmental contributors include endocrine-disrupting chemicals (EDCs) such as bisphenol A (BPA), phthalates, and persistent organic pollutants (POPs), which interfere with nuclear receptor signaling (e.g., androgen, estrogen, PPARγ receptors), alter steroidogenic enzyme expression, and promote adipogenesis and inflammation. Chronic low-grade inflammation—driven by gut dysbiosis, dietary patterns high in refined carbohydrates and saturated fats, and sedentary behavior—further potentiates ovarian and adrenal androgen production via cytokine-mediated activation of ovarian theca cells and adrenal zona reticularis. Finally, iatrogenic causes—including exogenous androgen administration, anabolic steroid use, or inadvertent exposure to contaminated supplements—must be considered in atypical presentations. Comprehensive evaluation requires biochemical profiling (total/free testosterone, DHEA-S, androstenedione, 17-OH progesterone, prolactin, LH/FSH ratio), pelvic ultrasound, and exclusion of malignancy or NCAH when indicated. Early identification and multidisciplinary management—including lifestyle intervention, insulin-sensitizing agents, and anti-androgen therapy—are critical to mitigate long-term reproductive, metabolic, and cardiovascular sequelae.

Hyperandrogenism refers to a clinical state characterized by excessive circulating levels of androgens—primarily testosterone, androstenedione, dehydroepiandrosterone (DHEA), and DHEA sulfate (DHEAS)—or increased peripheral androgen activity, leading to virilizing or non-virilizing manifestations. It is most commonly encountered in reproductive-aged women and constitutes a cornerstone diagnostic consideration in the Department of Reproductive Medicine. Early symptoms often emerge insidiously during adolescence or early adulthood and may be overlooked due to their gradual onset and overlap with normal pubertal development. These include subtle but progressive acne—particularly inflammatory, nodulocystic lesions on the jawline, chin, and upper back—alongside persistent seborrhea and oily skin. Mild hirsutism—defined as terminal hair growth in androgen-sensitive areas such as the upper lip, chin, sideburns, chest, lower abdomen (midline below the umbilicus), and inner thighs—may begin as sparse, coarse, pigmented hairs that gradually increase in density and distribution over months to years. Menstrual irregularity frequently presents early as oligomenorrhea (cycles >35 days) or secondary amenorrhea (>6 consecutive months without menses), reflecting chronic anovulation. Some patients report premenstrual worsening of mood, irritability, or fatigue, though these are nonspecific and require careful contextual interpretation. Importantly, early hyperandrogenism may manifest solely as biochemical abnormalities—elevated total or free testosterone, elevated DHEAS, or increased androstenedione—without overt phenotypic signs, especially in lean individuals or those with genetic polymorphisms affecting androgen receptor sensitivity.

Typical symptoms represent more pronounced, clinically evident manifestations. Moderate-to-severe hirsutism—quantified using the modified Ferriman-Gallwey score (mFG ≥8)—is hallmark, often accompanied by androgenic alopecia (female-pattern hair loss: thinning at the crown and frontal scalp with preservation of the frontal hairline). Acne becomes recalcitrant to conventional topical therapies and may involve scarring. Acanthosis nigricans—a velvety, hyperpigmented, hyperkeratotic plaque typically at the nape of the neck, axillae, or groin—is a cutaneous marker of insulin resistance and frequently co-occurs. Voice deepening, clitoromegaly (clitoral index >3.5 cm²), temporal balding, and increased muscle mass are late or severe features, suggesting prolonged, high-grade androgen excess and warranting urgent evaluation for non-ovarian sources (e.g., adrenal tumors or ovarian stromal hyperplasia).

Accompanying symptoms reflect downstream endocrine-metabolic consequences. Infertility is prevalent due to chronic anovulation and impaired folliculogenesis. Patients commonly report weight gain—especially central adiposity—and difficulty losing weight, even with dietary modification. Sleep disturbances, including snoring and daytime somnolence, may indicate comorbid obstructive sleep apnea, which is highly associated with obesity and insulin resistance in this population. Mood disorders—including anxiety, depression, and reduced quality of life—are significantly more prevalent than in age-matched controls, likely mediated by both hormonal dysregulation and psychosocial burden of visible stigmata. Some women experience decreased libido despite elevated androgens, possibly due to concomitant estrogen deficiency, psychological distress, or altered androgen metabolism.

Complications arise from sustained hormonal imbalance and its metabolic sequelae. Long-term anovulation increases endometrial exposure to unopposed estrogen, elevating risk for endometrial hyperplasia and, ultimately, endometrial adenocarcinoma. Insulin resistance predisposes to type 2 diabetes mellitus, dyslipidemia (elevated triglycerides, low HDL-C), and non-alcoholic fatty liver disease (NAFLD). Cardiovascular morbidity—including hypertension, endothelial dysfunction, and accelerated atherosclerosis—is elevated, independent of BMI. Ovarian complications include polycystic ovary morphology (PCOM) on ultrasound and, rarely, luteinized unruptured follicle syndrome or ovarian torsion in cases of marked ovarian enlargement. In rare cases of adrenal or ovarian neoplasms, rapid symptom progression may herald malignancy.

Diagnosis relies on a structured, stepwise approach. Initial evaluation includes detailed menstrual, dermatologic, and family history; physical examination assessing hirsutism (mFG score), acne severity, acanthosis nigricans, blood pressure, BMI, and signs of virilization (clitoromegaly, temporal balding, voice change). First-line biochemical testing comprises serum total testosterone (by LC-MS/MS for accuracy), sex hormone-binding globulin (SHBG), calculated free testosterone, DHEAS, and androstenedione. Prolactin and thyroid-stimulating hormone (TSH) are measured to exclude confounding endocrinopathies. If clinical suspicion remains high despite normal initial androgens, dynamic testing may be indicated: the 24-hour urinary free cortisol and dexamethasone suppression test rule out Cushing syndrome; the ACTH stimulation test evaluates for nonclassic congenital adrenal hyperplasia (NCAH); and pelvic ultrasound assesses ovarian volume (>10 mL), follicle count (>20 per ovary), and stromal echogenicity. In cases of rapid-onset virilization, imaging—contrast-enhanced CT or MRI of adrenals and pelvis—is mandatory to detect tumors.

Differential diagnosis is critical to avoid misattribution. Polycystic ovary syndrome (PCOS) accounts for ~70–80% of hyperandrogenism cases and is diagnosed using Rotterdam criteria (two of: oligo/anovulation, clinical/biochemical hyperandrogenism, PCOM on ultrasound), after excluding other etiologies. NCAH, caused by 21-hydroxylase deficiency, presents with elevated 17-hydroxyprogesterone (>2 ng/mL basally or post-ACTH), often with premature pubarche. Hyperprolactinemia suppresses GnRH pulsatility, causing anovulation and mild hyperandrogenism via reduced SHBG and increased ovarian androgen production. Cushing syndrome manifests with central obesity, moon facies, purple striae, and hypertension alongside hyperandrogenism; elevated late-night salivary cortisol or abnormal dexamethasone suppression confirms diagnosis. Androgen-secreting tumors (adrenal cortical carcinoma, ovarian Sertoli-Leydig cell tumor) cause abrupt, severe virilization and markedly elevated androgens (e.g., testosterone >200 ng/dL); imaging reveals a discrete mass. Idiopathic hirsutism—normal androgen levels with isolated hirsutism—represents increased peripheral 5-alpha reductase activity or heightened hair follicle sensitivity. Finally, iatrogenic causes—including anabolic steroid use, danazol, or certain progestins—must be explicitly ruled out through medication review. Accurate differentiation guides targeted management, prevents unnecessary interventions, and ensures timely oncologic referral when indicated.

Hyperandrogenism is a clinical endocrine disorder characterized by excessive circulating androgen levels or increased peripheral androgen activity, commonly presenting with hirsutism, acne, alopecia, menstrual irregularities (e.g., oligo- or amenorrhea), and infertility. In the Department of Reproductive Medicine, hyperandrogenism is most frequently associated with polycystic ovary syndrome (PCOS), though other etiologies—including non-classical congenital adrenal hyperplasia (NCAH), hyperprolactinemia, Cushing’s syndrome, and androgen-secreting tumors—must be systematically excluded via biochemical evaluation (total and free testosterone, DHEA-S, androstenedione, 17-hydroxyprogesterone, prolactin, cortisol, ACTH) and pelvic ultrasound. Management is individualized based on symptom severity, reproductive goals, metabolic comorbidities (e.g., insulin resistance, obesity, dyslipidemia), and patient preference.

Conservative treatment forms the cornerstone of initial management, particularly for overweight or obese patients with PCOS-related hyperandrogenism. Lifestyle modification—including structured caloric restriction (500–750 kcal/day deficit), moderate-intensity aerobic and resistance exercise (≥150 minutes/week), and behavioral counseling—has demonstrated robust efficacy: weight loss of ≥5% body weight consistently improves ovarian function, reduces free testosterone by 20–30%, restores ovulation in ~60% of anovulatory women, and enhances insulin sensitivity. Dietary approaches emphasizing low glycemic index foods, high-fiber intake, and adequate protein support hormonal balance and mitigate postprandial hyperinsulinemia, which exacerbates ovarian androgen synthesis. Sleep hygiene optimization and stress reduction techniques (e.g., mindfulness-based stress reduction) are adjunctive, given the bidirectional relationship between hypothalamic-pituitary-adrenal axis dysregulation and androgen excess.

Pharmacologic therapy is indicated when conservative measures are insufficient or contraindicated, or when rapid symptom control is required. First-line agents include combined oral contraceptives (COCs) containing ethinyl estradiol (20–35 μg) and anti-androgenic progestins (e.g., drospirenone, cyproterone acetate, or dienogest). COCs suppress LH-driven ovarian androgen production, increase sex hormone-binding globulin (SHBG), and reduce free testosterone bioavailability; clinical improvement in hirsutism typically requires 6–12 months. For patients desiring conception or intolerant to COCs, insulin-sensitizing agents are pivotal: metformin (1500–2000 mg/day) improves ovulation rates and reduces hyperandrogenemia, especially in insulin-resistant individuals. Spironolactone (50–200 mg/day), a competitive androgen receptor antagonist, is highly effective for hirsutism and acne but is contraindicated in pregnancy and requires monthly pregnancy testing and concomitant contraception. Finasteride (2.5–5 mg/day), a 5α-reductase inhibitor, may be added for refractory hirsutism, though evidence remains less robust than for spironolactone. In select cases—such as NCAH—low-dose glucocorticoids (e.g., hydrocortisone 10–20 mg/day) suppress adrenal androgen overproduction. Gonadotropin-releasing hormone (GnRH) analogues are reserved for severe, treatment-refractory cases due to their profound hypoestrogenic effects and bone mineral density risks.

Surgical intervention is rarely indicated but plays a defined role in specific contexts. Laparoscopic ovarian drilling (LOD) remains a second-line fertility treatment for clomiphene-resistant anovulatory PCOS. Performed under general anesthesia, LOD involves creating 4–10 punctures (3–5 mm depth) in each ovary using monopolar or bipolar energy, thereby reducing theca cell mass and local intraovarian androgen production. Meta-analyses report ovulation resumption in 70–80% and pregnancy rates of 50–60% within 12 months post-procedure, with lower multiple gestation risk compared to gonadotropin therapy. However, LOD carries procedural risks—including adhesion formation, ovarian failure (rare), and potential long-term decline in AMH—and is thus reserved for carefully selected patients after thorough counseling. Adrenalectomy or oophorectomy is only considered for confirmed, unilateral androgen-secreting adrenal or ovarian tumors, confirmed via imaging (contrast-enhanced CT/MRI) and selective venous sampling when localization is uncertain.

Treatment advantages in China reflect integrated, multidisciplinary care models increasingly adopted in tertiary reproductive medicine centers. These institutions offer standardized diagnostic algorithms aligned with international guidelines (e.g., Androgen Excess and PCOS Society criteria) while incorporating traditional Chinese medicine (TCM) adjuncts—such as acupuncture and herbal formulations (e.g., modified Gui Zhi Fu Ling Wan)—with emerging evidence supporting synergistic improvements in insulin sensitivity and menstrual regularity. Advanced digital health platforms enable remote monitoring of anthropometrics, glucose profiles, and medication adherence, enhancing longitudinal care continuity. Moreover, China’s national health insurance system now covers key diagnostics (e.g., serum androgen panels, pelvic ultrasound) and first-line therapeutics (metformin, spironolactone, COCs) at subsidized rates, improving accessibility. Robust clinical trial infrastructure supports rapid translation of novel therapies, including next-generation anti-androgens and selective androgen receptor modulators currently under phase II investigation in Shanghai and Beijing centers.

Recovery and long-term management emphasize sustained lifestyle engagement and vigilant surveillance. Patients should undergo annual assessment of fasting glucose, HbA1c, lipid profile, blood pressure, and BMI; transvaginal ultrasound every 2–3 years if oligomenorrheic to monitor endometrial thickness and exclude hyperplasia. Hormonal contraception should be continued until conception is actively pursued, with preconception counseling addressing folic acid supplementation, weight optimization, and discontinuation timing. For those undergoing LOD, postoperative pelvic physiotherapy may reduce adhesion-related pain, and serial AMH measurement helps assess ovarian reserve trajectory. Psychological support is integral: validated screening tools (e.g., Hospital Anxiety and Depression Scale) should be administered routinely, given the high prevalence of depression and body image distress in hyperandrogenic women. Finally, patient education—delivered via bilingual (Mandarin–English) digital modules and peer-led support groups—empowers self-management, improves treatment concordance, and fosters resilience across the reproductive lifespan.